Skip to main content
. 2016 Oct 13;8(3):5540–5565. doi: 10.18632/oncotarget.12649

Figure 1. Structures of Bcr-Abl1 and ALK inhibitors.

Figure 1

In panel A the molecular structures of main Bcr-Abl1 inhibitors, Imatinib, Nilotinib, Dasatinib, Bosutinib and Ponatinib are reported. In panel B the structures of ALK inhibitors, Crizotinib, Ceritinib, Alectinib, Brigatinib and Entrectinib, are shown.